AbbVie's Allergan division has launched Boey, a botulinum toxin formulation designed for rapid onset, and has secured EU regulatory approval. The product targets the competitive gap where practitioners and patients seek faster results—traditionally a weakness of toxin injectables, which typically require 3–7 days for full effect.
Injectables
AbbVie Launches Boey, Rapid-Onset Botulinum Toxin, With EU Approval
New formulation claims faster onset than Botox; FDA pathway in U.S. unclear.
1-YEAR MOVE
ABBV▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
AbbVie's Boey claims faster onset than traditional Botox; EU approved, U.S. pathway unclear.
Boey's mechanism and potency relative to Botox remain proprietary, but the rapid-onset claim, if clinically validated, could reshape toxin prescribing patterns. AbbVie has not disclosed a U.S. FDA pathway or timeline. For practice owners, the strategic question is whether Boey will command a premium price or be positioned as a value alternative. Either way, it signals that the toxin category—long considered mature—is still innovating, and that differentiation on onset speed is now table stakes.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.